Welcome to our dedicated page for Adc Therapeutics Sa news (Ticker: ADCT), a resource for investors and traders seeking the latest updates and insights on Adc Therapeutics Sa stock.
ADC Therapeutics SA reports news on its commercial-stage oncology business focused on antibody-drug conjugates. The company markets ZYNLONTA (loncastuximab tesirine-lpyl), a CD19-directed ADC with FDA accelerated approval and European Commission conditional approval for relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy.
Recurring updates cover ZYNLONTA product revenue, manufacturing and commercialization activity, clinical development in combination regimens and earlier lines of therapy, including LOTIS program studies, and corporate financing matters. Company news also includes quarterly financial results, investor presentations, conference participation and equity inducement grants under its compensation plans.
ADC Therapeutics (NYSE: ADCT) announced two investigator-initiated study abstracts on ZYNLONTA accepted for presentation at the 66th ASH Annual Meeting. The Phase 2 study combining ZYNLONTA with rituximab in relapsed/refractory follicular lymphoma showed a 97.1% overall response rate among 35 patients, with an 80% best complete metabolic response rate. In a separate study for relapsed/refractory marginal zone lymphoma, ZYNLONTA as a single agent achieved an 85% overall response rate with 75% complete response rate in 20 evaluable patients. Both studies demonstrated safety profiles consistent with known ZYNLONTA data.
ADC Therapeutics (NYSE: ADCT), a commercial-stage leader in antibody drug conjugates, has announced its participation in two major investor conferences this November. The company will present at the Guggenheim Securities Healthcare Innovation Conference on November 11, 2024, at 11:00 a.m. ET, and the Jefferies London Healthcare Conference on November 19, 2024, at 11:00 a.m. GMT. Both presentations will feature CEO Ameet Mallik in fireside chat formats. Live webcasts will be available on the company's investor relations website, with replays accessible for approximately 30 days after each event.
ADC Therapeutics announced the grant of options to purchase 42,000 common shares to two new employees as employment inducement. The grants, approved by the Compensation Committee under the Company's Inducement Plan, will vest over four years, with 25% vesting on the first anniversary and 1/48th monthly thereafter until full vesting on the fourth anniversary, subject to continued employment.
ADC Therapeutics (NYSE: ADCT) announced it will host a conference call and live webcast on November 7, 2024, at 8:30 a.m. EST to discuss third quarter 2024 financial results and provide business updates. North American and Canadian participants can join via toll-free number 1-800-836-8184. The webcast will be available under 'Events and Presentations' on the company's investor relations website and archived for 30 days after the call.
ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader in antibody drug conjugates (ADCs), has announced the granting of options to purchase 113,700 common shares to six new employees on October 1, 2024. These grants were approved by the Compensation Committee of the Company's Board of Directors under the Company's Inducement Plan as a material inducement to employment.
The options will vest and become exercisable in stages: 25% on the first anniversary of the grant date, and 1/48th monthly thereafter, becoming fully vested after four years, subject to continued employment. This action aligns with NYSE's Listed Company Manual Rule 303A.08, emphasizing ADC Therapeutics' commitment to attracting and retaining top talent in the competitive field of ADCs.
ADC Therapeutics SA (NYSE: ADCT), a leader in antibody drug conjugates (ADCs), has granted options to purchase 17,900 common shares to four new employees on September 3, 2024. These grants, approved by the Compensation Committee, are part of the company's Inducement Plan to attract and retain top talent. The options will vest over four years, with 25% vesting on the first anniversary and 1/48th vesting monthly thereafter, contingent on continued employment. This move aligns with NYSE's Listed Company Manual Rule 303A.08, demonstrating ADC Therapeutics' commitment to incentivizing high performance and long-term success.
ADC Therapeutics SA (NYSE: ADCT), a leader in antibody drug conjugates, has announced its participation in two major investor conferences this September. The company will be represented by CEO Ameet Mallik at both events:
1. H.C. Wainwright 26th Annual Global Investment Conference on September 9, 2024, featuring a virtual fireside chat at 7:00 a.m. ET.
2. 10th Cantor Global Healthcare Conference 2024 on September 18, 2024, with a fireside chat scheduled from 11:30-12:00 p.m. ET.
Live webcasts of both presentations will be accessible through the company's website, with replays available for approximately 30 days after each event.
ADC Therapeutics reported Q2 2024 financial results and operational updates. ZYNLONTA achieved commercial profitability in H1 2024, with net sales of $17.0 million in Q2. The LOTIS-7 trial is progressing, with efficacy and safety data expected by year-end 2024. LOTIS-5 trial enrollment is expected to complete before year-end 2024. The company's cash position of $300.1 million is expected to extend runway into mid-2026.
Financial highlights include:
- Net product revenues of $34.9 million for H1 2024
- R&D expense decreased to $50.0 million for H1 2024
- Net loss of $83.2 million, or $0.93 per share for H1 2024
- Adjusted net loss of $55.5 million, or $0.62 per share for H1 2024
ADC Therapeutics SA (NYSE: ADCT), a leader in antibody drug conjugates (ADCs), has granted options to purchase 38,600 common shares to three new employees on August 1, 2024. These grants, approved by the Compensation Committee, are part of the company's Inducement Plan to attract and retain top talent. The options will vest over four years, with 25% vesting on the first anniversary and 1/48th vesting monthly thereafter, contingent on continued employment. This action aligns with NYSE's Listed Company Manual Rule 303A.08 for employment inducement exemptions.
ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader in antibody drug conjugates (ADCs), has announced a conference call and live webcast scheduled for August 6, 2024, at 8:30 a.m. EDT. The event will cover the company's second quarter 2024 financial results and provide operational updates. Interested parties can register for the call to receive dial-in details and a unique PIN. A live webcast will be available on the company's investor relations website, with an archived version accessible for 30 days after the event.